The Global Insulin Sensitizers Market Size is valued at USD 14.27 billion in 2022 and is predicted to reach USD 23.35 billion by the year 2031 at a 5.8% CAGR during the forecast period for 2023-2031.
Thiazolidinediones (TZDs) are referred to as "insulin sensitizers" and are also euglycemics, which normalize blood sugar. Type 2 diabetes mellitus (T2DM) has insulin sensitizers as its accepted underlying cause. Due to the restricted prescription or removal from the market of several licenced insulin sensitizers, such as thiazolidinediones (TZDs), due to safety concerns, there is now an unmet demand for safe and effective insulin sensitizers. Therefore, diabetic patients will greatly benefit from effective insulin sensitizers devoid of TZD-like adverse effects.
The World Health Organisation predicts that the morbidity of diabetes mellitus (DM), a noninfectious pandemic disease that affects the entire world, will continue to climb in the ensuing decades, which is anticipated to drive market growth. The rise in insulin sensitizers in the general population, which is the pervasive occurrence of obesity and metabolic syndrome, is responsible for the rise in type 2 diabetes (T2DM), which affects more than 90% of diabetic patients, which is another characteristic propelling the market growth during the forecast period.
Insulin sensitizers are a pathological condition where the target cells in the liver, skeletal muscle, and adipose tissue fail to respond to insulin adequately, impairing their ability to absorb and metabolize glucose effectively.
The insulin sensitizers market is segmented on the basis of the type of insulin sensitizers, indication, and distribution channel. Based on the type of insulin sensitizers, the market is segmented as thiazolidinediones (TZDs), biguanides, incretin-based indication, and others. By indication, the market is segmented into type 2 diabetes, prediabetes, and polycystic ovary syndrome (PCOS). On the basis of distribution channels includes hospital pharmacies, retail pharmacies, and online pharmacies.
The thiazolidinediones (TZDs) category is expected to hold a major share of the global insulin sensitizers market in 2022. This is attributed to Thiazolidinediones (TZDs) helping to lower blood sugar by improving muscle, fat, and liver sensitivity to insulin. TZDs are referred to as "insulin sensitizers" and "euglycemics," which are medications that help bring blood sugar levels back into the normal range without increasing the danger of low blood sugar.
The type 2 diabetes category is projected to develop at a fast rate in the global insulin sensitizers market. Type 2 diabetes mellitus is a disorder that is becoming more common and is linked to numerous metabolic abnormalities. The most noticeable characteristic of type 2 diabetes and the related metabolic problems is insulin resistance. Insulin sensitizers have numerous positive effects on lipid metabolism and atherosclerotic vascular processes, in addition to their therapeutic effects on glycemic management, which is expected to drive market development during the forecast period.
The North America insulin sensitizers market is expected to show the highest market share in terms of revenue in the near future. Increasing clinical trials on insulin sensitizers in the region are anticipated to push the market growth. Furthermore, rising research and development for various insulin sensitizers boosts the market growth. Major Market players are focusing on competition in the market, which is one of the factors propelling the market development during the forecast period.
| Report Attribute | Specifications |
| Market size value in 2022 | USD 14.27 Bn |
| Revenue forecast in 2031 | USD 23.35 Bn |
| Growth rate CAGR | CAGR of 5.8 % from 2023 to 2031 |
| Quantitative units | Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments covered | By Type Of Insulin Sensitizers, Indication, And Distribution Channel |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Insulin Sensitizers Market By Type of Insulin Sensitizers-
Insulin Sensitizers Market By Indication-
Insulin Sensitizers Market By Distribution channel-
Insulin Sensitizers Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Insulin Sensitizers Market Snapshot
Chapter 4. Global Insulin Sensitizers Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type of Insulin Sensitizers Estimates & Trend Analysis
5.1. By Type of Insulin Sensitizers, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Type of Insulin Sensitizers:
5.2.1. Thiazolidinediones (TZDs)
5.2.2. Biguanides
5.2.3. Incretin-based therapies
5.2.4. Others
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. By Indication & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Indication:
6.2.1. Type 2 Diabetes
6.2.2. Prediabetes
6.2.3. Polycystic Ovary Syndrome (PCOS)
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. By Route of Administration & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Route of Administration:
7.2.1. Oral
7.2.2. Injectable
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. By Distribution Channel & Market Share, 2020 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Insulin Sensitizers Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Insulin Sensitizers Market revenue (US$ Million) estimates and forecasts By Type of Insulin Sensitizers, 2019-2031
9.1.2. North America Insulin Sensitizers Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031
9.1.3. North America Insulin Sensitizers Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031
9.1.4. North America Insulin Sensitizers Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031
9.1.5. North America Insulin Sensitizers Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
9.2. Europe
9.2.1. Europe Insulin Sensitizers Market revenue (US$ Million) By Type of Insulin Sensitizers, 2019-2031
9.2.2. Europe Insulin Sensitizers Market revenue (US$ Million) By Indication, 2019-2031
9.2.3. Europe Insulin Sensitizers Market revenue (US$ Million) By Route of Administration, 2019-2031
9.2.4. Europe Insulin Sensitizers Market revenue (US$ Million) By Distribution Channel, 2019-2031
9.2.5. Europe Insulin Sensitizers Market revenue (US$ Million) by country, 2019-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Insulin Sensitizers Market revenue (US$ Million) By Type of Insulin Sensitizers, 2019-2031
9.3.2. Asia Pacific Insulin Sensitizers Market revenue (US$ Million) By Indication, 2019-2031
9.3.3. Asia Pacific Insulin Sensitizers Market revenue (US$ Million) By Route of Administration, 2019-2031
9.3.4. Asia Pacific Insulin Sensitizers Market revenue (US$ Million) By Distribution Channel, 2019-2031
9.3.5. Asia Pacific Insulin Sensitizers Market revenue (US$ Million) by country, 2019-2031
9.4. Latin America
9.4.1. Latin America Insulin Sensitizers Market revenue (US$ Million) By Type of Insulin Sensitizers, (US$ Million) 2019-2031
9.4.2. Latin America Insulin Sensitizers Market revenue (US$ Million) By Indication, (US$ Million) 2019-2031
9.4.3. Latin America Insulin Sensitizers Market revenue (US$ Million) By Route of Administration, (US$ Million) 2019-2031
9.4.4. Latin America Insulin Sensitizers Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
9.4.5. Latin America Insulin Sensitizers Market revenue (US$ Million) by country, 2019-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Insulin Sensitizers Market revenue (US$ Million) By Type of Insulin Sensitizers, (US$ Million) 2019-2031
9.5.2. Middle East & Africa Insulin Sensitizers Market revenue (US$ Million) By Indication, (US$ Million) 2019-2031
9.5.3. Middle East & Africa Insulin Sensitizers Market revenue (US$ Million) By Route of Administration, (US$ Million) 2019-2031
9.5.4. Middle East & Africa Insulin Sensitizers Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
9.5.5. Middle East & Africa Insulin Sensitizers Market revenue (US$ Million) by country, 2019-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Eli Lilly and Company
10.2.2. Novo Nordisk
10.2.3. Sanofi
10.2.4. Merck & Co.
10.2.5. Bristol Myers Squibb
10.2.6. AstraZeneca
10.2.7. Boehringer Ingelheim
10.2.8. Johnson & Johnson
10.2.9. Takeda Pharmaceutical